BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11575296)

  • 1. Trastuzumab and breast cancer.
    Strasser F; Betticher DC; Suter TM
    N Engl J Med; 2001 Sep; 345(13):996. PubMed ID: 11575296
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab cardiac side effects: only time will tell.
    Levine MN
    J Clin Oncol; 2005 Nov; 23(31):7775-6. PubMed ID: 16258081
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice.
    Goel S; Beith JM
    J Clin Oncol; 2011 Mar; 29(7):e175-6. PubMed ID: 21189375
    [No Abstract]   [Full Text] [Related]  

  • 5. Irreversible cardiotoxicity after adjuvant treatment with trastuzumab in a case of breast cancer.
    Bordin P; Volpe C; Adami G; Moretti V; Ermacora P
    Tumori; 2008; 94(5):777-8. PubMed ID: 19112961
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-induced cardiac dysfunction.
    Panjrath GS; Jain D
    Nucl Med Commun; 2007 Feb; 28(2):69-73. PubMed ID: 17198344
    [No Abstract]   [Full Text] [Related]  

  • 8. Trastuzumab and breast cancer.
    Palmieri C; Powles T; Vigushin D
    N Engl J Med; 2001 Sep; 345(13):996-7. PubMed ID: 11575297
    [No Abstract]   [Full Text] [Related]  

  • 9. Can modern echocardiographic techniques predict drug-induced cardiotoxicity?
    Edvardsen T
    J Am Coll Cardiol; 2011 May; 57(22):2271-2. PubMed ID: 21616288
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2-positive breast cancer: current treatment strategies.
    Perez EA; Baweja M
    Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity of trastuzumab in clinical practice.
    McArthur HL; Chia S
    N Engl J Med; 2007 Jul; 357(1):94-5. PubMed ID: 17611218
    [No Abstract]   [Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
    J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab in breast cancer.
    Gilbert SG
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16467555
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of trastuzumab-related cardiac dysfunction.
    Carver JR
    Prog Cardiovasc Dis; 2010; 53(2):130-9. PubMed ID: 20728700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
    Morris PG; Hudis CA
    J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
    [No Abstract]   [Full Text] [Related]  

  • 18. Trastuzumab--mechanism of action and use.
    Mir O; Berveiller P; Pons G
    N Engl J Med; 2007 Oct; 357(16):1664-5; author reply 1665-6. PubMed ID: 17948347
    [No Abstract]   [Full Text] [Related]  

  • 19. Trastuzumab for early breast cancer.
    Thorat M
    Lancet; 2006 Jan; 367(9505):108. PubMed ID: 16413867
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.